Comparison of Clinical Outcomes of Definitive and Postoperative Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck: Can Definitive Radiotherapy Be a Treatment Option?
adenoid cystic carcinoma
definitive radiotherapy
head and neck cancer
postoperative radiotherapy
surgical resection
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Nov 2021
02 Nov 2021
Historique:
received:
25
09
2021
revised:
27
10
2021
accepted:
30
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
The standard treatment for adenoid cystic carcinoma of the head and neck is surgical resection followed by postoperative radiotherapy (PORT). Currently, definitive radiotherapy (defRT) is considered an inadequate treatment; however, its data are based on studies using classical radiotherapy techniques. Therefore, the therapeutic effects of current radiotherapy techniques have not been adequately evaluated, and it may have underestimated the efficacy of defRT. We retrospectively analyzed 44 adenoid cystic carcinoma patients treated with radiotherapy based on modern treatment techniques from 1993 to 2017. Twenty-four patients underwent PORT and 20 patients underwent defRT. The 5-year overall survival rates for patients treated with PORT and defRT were 85.3% and 79.7%, respectively. The 5-year local control rates were 82.5% and 83.1%, respectively. There were no statistically significant differences in the overall survival and local control of patients treated with PORT and defRT ( Our results show that defRT is comparable to surgical resection followed by PORT with respect to overall survival and local control. The results suggest that defRT can be an effective treatment option for adenoid cystic carcinoma of the head and neck.
Sections du résumé
BACKGROUND
BACKGROUND
The standard treatment for adenoid cystic carcinoma of the head and neck is surgical resection followed by postoperative radiotherapy (PORT). Currently, definitive radiotherapy (defRT) is considered an inadequate treatment; however, its data are based on studies using classical radiotherapy techniques. Therefore, the therapeutic effects of current radiotherapy techniques have not been adequately evaluated, and it may have underestimated the efficacy of defRT.
METHODS
METHODS
We retrospectively analyzed 44 adenoid cystic carcinoma patients treated with radiotherapy based on modern treatment techniques from 1993 to 2017.
RESULTS
RESULTS
Twenty-four patients underwent PORT and 20 patients underwent defRT. The 5-year overall survival rates for patients treated with PORT and defRT were 85.3% and 79.7%, respectively. The 5-year local control rates were 82.5% and 83.1%, respectively. There were no statistically significant differences in the overall survival and local control of patients treated with PORT and defRT (
CONCLUSION
CONCLUSIONS
Our results show that defRT is comparable to surgical resection followed by PORT with respect to overall survival and local control. The results suggest that defRT can be an effective treatment option for adenoid cystic carcinoma of the head and neck.
Identifiants
pubmed: 34771670
pii: cancers13215507
doi: 10.3390/cancers13215507
pmc: PMC8582871
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):152-9
pubmed: 16904520
Cancer. 2007 Dec 15;110(12):2726-31
pubmed: 17960615
Radiother Oncol. 2017 Jun;123(3):387-393
pubmed: 28528680
Radiother Oncol. 2013 Nov;109(2):262-8
pubmed: 24044797
Strahlenther Onkol. 1987 Feb;163(2):84-9
pubmed: 3031839
Cancer. 2012 Sep 15;118(18):4444-51
pubmed: 22294420
Cancer. 1986 Feb 1;57(3):519-24
pubmed: 3002583
Head Neck. 2004 Feb;26(2):154-62
pubmed: 14762884
J Clin Oncol. 2014 Sep 10;32(26):2847-54
pubmed: 25113761
Am J Surg. 1974 Oct;128(4):512-20
pubmed: 4371368
Cancer. 2012 Jun 1;118(11):2872-8
pubmed: 22020577
Oral Oncol. 2015 Jul;51(7):652-61
pubmed: 25943783
J Clin Invest. 2013 Jul;123(7):2965-8
pubmed: 23778141
Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):721-6
pubmed: 8018324
Oral Oncol. 2015 Jan;51(1):71-6
pubmed: 25456010
Head Neck Surg. 1986 Jan-Feb;8(3):177-84
pubmed: 3744850
Laryngoscope. 2004 Jul;114(7):1194-9
pubmed: 15235347
Nat Genet. 2013 Jul;45(7):791-8
pubmed: 23685749
Am J Otolaryngol. 2012 Sep-Oct;33(5):510-8
pubmed: 22226227
Am J Surg. 1997 Nov;174(5):495-8
pubmed: 9374223
Jpn J Clin Oncol. 2007 Nov;37(11):805-11
pubmed: 18057012
Cancer. 1984 Sep 15;54(6):1062-9
pubmed: 6088017
J Laryngol Otol. 2009 Oct;123(10):1137-44
pubmed: 19573256
Oral Oncol. 2006 Sep;42(8):759-69
pubmed: 16757203
Cancer Sci. 2017 Oct;108(10):2039-2044
pubmed: 28730646
Oral Oncol. 2017 Mar;66:58-63
pubmed: 28249649
Radiother Oncol. 2016 Feb;118(2):286-92
pubmed: 26867969
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):57-62
pubmed: 15936155
Int J Radiat Oncol Biol Phys. 1995 Jun 15;32(3):619-26
pubmed: 7790247
J Clin Oncol. 2019 Jun 20;37(18):1529-1537
pubmed: 30939095
Head Neck. 2011 Jun;33(6):905-11
pubmed: 20652885
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):639-646
pubmed: 29413278
Cancer. 1978 Jul;42(1):265-82
pubmed: 208752
Otolaryngol Head Neck Surg. 1992 Apr;106(4):332-8
pubmed: 1314372
Cancer. 1986 Jan 15;57(2):312-9
pubmed: 3002581
Int J Oral Maxillofac Surg. 1997 Dec;26(6):435-9
pubmed: 9418145
Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7
pubmed: 14623749